Posted by Michael Wonder on 27 Jun 2016
TGA publishes AusPAR for Xolair
27 June 2016 - The TGA has published an AusPAR for Novartis' Xolair (omalizumab).
The TGA approved Xolair on 28 January 2016 for use In children aged 6 to <12 years as add-on therapy to improve asthma control in patients with severe allergic asthma who have documented exacerbations despite daily high dose inhaled corticosteroids, and who have immunogloblin E levels corresponding to the recommended dose range.
